Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

PFS increase but no OS increase for niraparib in advanced ovarian cancer

ESMO 2024

13 - 17 Sep 2024

Published: 17 Sep 2024

Views: 25

Rating:

Save

Dr Antonio González-Martín - Cancer Center Clínica Universidad de Navarra, Madrid, Spain

Dr Antonio González-Martín talks to ecancer at ESMO 2024 about mixed results from the PRIMA / ENGOT-OV26 / GOG-3012 study.

This looked at newly diagnosed advanced ovarian cancer treated with niraparib for first-line maintenance.

While the trial continues to show an increase in progression free survival versus placebo, the overall survival figures were less encouraging, with a statistically insignificant decrease from 48.8 months for placebo versus 46.6 months for nirapirib.

Related Videos

ESMO 2024: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2024: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

ERBB2 amplifications across sex, race, and cancer types studied to guide HER2...

Dr Marc Machaalani - Dana-Farber Cancer Institute, Boston, USA

ERBB2 amplifications across sex, race, and cancer types studied to guide HER2 therapies ( Dr Marc Machaalani - Dana-Farber Cancer Institute, Boston, USA )

Cancer advocacy and fundraising in Nigeria

Dr Zainab Shinkafi-Bagudu - Founder, Medicaid Cancer Foundation

Cancer advocacy and fundraising in Nigeria ( Dr Zainab Shinkafi-Bagudu - Founder, Medicaid Cancer Foundation )

ASCO 2024: Advances in NSCLC

Dr Enriqueta Felip, Dr Alex Spira, Dr Antonio Passaro and Dr Alfredo Addeo

ASCO 2024: Advances in NSCLC ( Dr Enriqueta Felip, Dr Alex Spira, Dr Antonio Passaro and Dr Alfredo Addeo )

Monitoring ovarian function in oncology studies

Dr Elizabeth Trice Loggers - University of Washington, Seattle, USA

Monitoring ovarian function in oncology studies ( Dr Elizabeth Trice Loggers - University of Washington, Seattle, USA )

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

ASCO GU 2024: Current best practice for mRCC

Prof Jens Bedke, Prof Thomas Powles, Prof Michael Staehler and Dr Wenxin Xu

ASCO GU 2024: Current best practice for mRCC ( Prof Jens Bedke, Prof Thomas Powles, Prof Michael Staehler and Dr Wenxin Xu )

Updates on lung cancer from WCLC and ESMO 2023

Dr Luis Raez - Memorial Cancer Institute, Miami, USA

Updates on lung cancer from WCLC and ESMO 2023 ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )

The treatment of cervical cancer in the presence of HIV in Sub-Saharan Africa

Dr Ntokozo Ndlovu - University of Zimbabwe, Harare, Zimbabwe

The treatment of cervical cancer in the presence of HIV in Sub-Saharan Africa ( Dr Ntokozo Ndlovu - University of Zimbabwe, Harare, Zimbabwe )

More from ecancer